title: Treatment with probiotics in experimental oral colonization by Candida albicans in murine model (DBA/2).
abstract: The aim of this study is to evaluate the oral colonization by Candida albicans in experimental murine immunosuppressed DBA/2 and treatment with probiotic bacteria. To achieve these objectives, 152 DBA/2-immunosuppressed mice were orally inoculated with a suspension of C. albicans containing 10(8) viable yeast cells, the animals were treated with nystatin or with the probiotics (Lactobacillus acidophilus and Lactobacillus rhamnosus). Evaluations were performed by Candida count from oral mucosa swabbing. The oral mucosa colonization by C. albicans started at day 1 after inoculation, remained maximal from day 3 until day 7, and then decreased significantly. Probiotics reduced the C. albicans colonization significantly on the oral mucosa in comparison with the untreated animal group. In the group treated with L. rhamnosus, the reduction in yeast colonization was significantly higher compared with that of the group receiving nystatin. Immunosuppressed animal model DBA/2 is a relevant model for experimental Candida oral colonization, and the treatment with probiotics in this model may be an effective alternative to prevent it.
authors: Department of Prosthesis, University of São Paulo, School of Dentistry, São Paulo, Brazil.
authors: V H
authors: VH
authors: Matsubara
authors: E G
authors: EG
authors: Silva
authors: C R
authors: CR
authors: Paula
authors: K H
authors: KH
authors: Ishikawa
authors: A E M
authors: AE
authors: Nakamae
mesh_terms: D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D002175:Candida / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000188:drug therapy / Q000628:therapy*; D015169:Colony Count, Microbial; D003520:Cyclophosphamide / Q000008:administration & dosage; D004195:Disease Models, Animal; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007779:Lactobacillus acidophilus; D052201:Lacticaseibacillus rhamnosus; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D009061:Mouth Mucosa / Q000382:microbiology; D009761:Nystatin / Q000627:therapeutic use; D010159:Palate / Q000382:microbiology; D019936:Probiotics / Q000627:therapeutic use*; D011897:Random Allocation; D014059:Tongue / Q000382:microbiology
chemical_list: D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D009761:Nystatin; D003520:Cyclophosphamide